Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
Objective New anti-cancer drugs promise to increased survival benefits and reduce adverse events. Trastuzumab emtansine (T-DM1) is a novel anti-human epidermal growth factor receptor 2 agent that has shown minimal cardiotoxicity in clinical trials. However, data on real-life outcomes are required. M...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-12-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605211053755 |